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Background: Chagas disease, which is caused by Trypanosoma cruzi, is a major health problem in Latin America,
and there are currently no drugs for the effective treatment of this disease. The energy metabolism of T. cruzi is an
attractive target for drug design, and we previously reported that inhibitors of α-hydroxy acid dehydrogenase
(HADH)-isozyme II exhibit trypanocidal activity. N-Propyl oxamate (NPOx) is an inhibitor of HADH-isozyme II, and its
non-polar ethyl ester (Et-NPOx) is cytotoxic to T. cruzi. A new derivative of NPOx has been developed in this study
with higher trypanocidal activity, which could be used for the treatment of Chagas disease.
Methods: The benzyl ester of NPOx (B-NPOx) was synthesized and its activity evaluated towards epimastigotes and
bloodstream trypomastigotes (in vitro), as well as mice infected with T. cruzi (in vivo). The activity of B-NPOx was also
compared with those of Et-NPOx, benznidazole (Bz) and nifurtimox (Nx). NINOA, Miguz, Compostela, Nayarit and
INC-5 T. cruzi strains were used in this study.
Results: Polar NPOx did not penetrate the parasites and exhibited no trypanocidal activity. In contrast, the
hydrophobic ester B-NPOx exhibited trypanocidal activity in vitro and in vivo. B-NPOx exhibited higher trypanocidal
activity than Et-NPOx, Bz and Nx towards all five of the T. cruzi strains. The increased activity of B-NPOx was attributed
to its hydrolysis inside the parasites to give NPOx and benzyl alcohol, which is an antimicrobial compound with
trypanocidal effects. B-NPOx was also effective against two strains of T. cruzi that are resistant to Bz and Nx.
Conclusion: B-NPOx exhibited higher in vitro (2- to 14.8-fold) and in vivo (2.2- to 4.5-fold) trypanocidal activity
towards T. cruzi than Et-NPOx. B-NPOx also exhibited higher in vitro (2- to 24-fold) and in vivo (1.9- to 15-fold)
trypanocidal activity than Bz and Nx. B-NPOx is more lipophilic than Et-NPOx, allowing for better penetration
into T. cruzi parasites, where the enzymatic cleavage of B-NPOx would give NPOx and benzyl alcohol, which are
potent trypanocidal agents. Taken together with its low toxicity, these results suggest that B-NPOx could be
used as a potent prodrug for the treatment of Chagas disease.
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Chagas disease is a parasitic disease caused by Trypano-
soma cruzi (T. cruzi), which can be transmitted to humans
by hematophagous bugs or as a direct consequence of a
blood transfusion using infected blood. Chagas disease is
endemic in Latin America, where it affects 8–10 million
people. Furthermore, Chagas disease causes about 50,000
deaths per year in Latin America, and approximately 25%
of the population is at risk of acquiring the disease [1-3].
There are currently very few drugs available for the treat-
ment of Chagas disease, which is therefore considered to
be a “neglected” disease. Furthermore, the drugs currently
available for the treatment of Chagas disease, including
benznidazole (Bz) and nifurtimox (Nx), are only weakly ef-
ficacious against this disease and therefore generally fail to
restore patients to full health [4]. The acute phase of the
disease appears shortly after infection, and the chronic
phase appears after a silent asymptomatic period that can
last for several years. The heart, esophagus, colon and per-
ipheral nervous system can be irreversibly damaged dur-
ing the chronic phase of Chagas disease, and the majority
of patients usually die from heart failure [5,6].
Although Bz and Nx can be effective treatments during
the acute phase of Chagas disease, they are not effective
against every known strain of T. cruzi [7]. Nx has been re-
ported to exert its activity via the induction of oxidative
stress [8], whereas Bz exerts its activity by producing
DNA damage, as well as inhibiting protein synthesis and
the respiratory chain [9]. It was recently shown that a try-
panosomal type I nitroreductase plays a key role in the ac-
tivation of Bz and Nx via an oxygen-insensitive pathway,
which leads to the formation of a series of highly cytotoxic
metabolites, including glyoxal and several nitriles. These
types of cytotoxic metabolites can readily react with a var-
iety of other biological molecules to form adducts, which
could account for the pleiotropic effects observed in try-
panosomes treated with these prodrugs [10,11]. The weak
effects of Bz and Nx during the chronic phase of Chagas
disease can be attributed to their relatively short half-lives,
as well as their poor permeability properties, which afford
them limited tissue penetration [12]. Based on these limi-
tations, there is currently a lack of effective drugs for the
treatment of Chagas disease, and several new approaches
have been developed in an attempt to identify novel drugs
that target specific metabolic pathways that are critical to
the survival of T. cruzi [13].
Inhibitors of ergosterol biosynthesis, such as posacona-
zole and albaconazole, are highly effective for the treatment
of fungal diseases, and several compounds belonging to
this particular class have also been shown to exhibit activity
against T. cruzi, making them suitable candidates for clin-
ical use [14]. K-777 is an inhibitor of cruzipain, which is a
cysteine protease that blocks the proliferation of T. cruzi
[15]. Unfortunately, however, the clinical use of K-777 as atherapeutic agent for the treatment for Chagas disease has
been limited by its hepatotoxicity. Inhibitors of pyrophos-
phate metabolism have multiple enzymatic targets, includ-
ing squalene synthase, farnesyl pyrophosphate synthase,
proton-pumping pyrophosphatase [12] and hexokinase
[16], and compounds belonging to this class have been re-
ported to exhibit activity against T. cruzi, although their
clinical use is still under investigation. Inhibitors of trypa-
nothione have been reported to show trypanocidal activity
in vitro, but there is currently no evidence to suggest that
they can behave in a selective manner in vivo [17]. Zylo-
prim (allopurinol), which is an inhibitor of purine metabol-
ism that is currently used for the treatment of gout in
humans, has been shown to exhibit activity towards trypa-
nosomatides, although the activity of this compound to-
wards T. cruzi in humans has been the subject of some
controversy, and several other purine metabolism inhibi-
tors are currently being evaluated [18].
Glycolysis has been identified as the only ATP-generating
process in T. cruzi parasites [19], and it was consequently
envisaged that the treatment of these organisms with inhib-
itors capable of reducing their level of glycolytic flux would
result in their death [20]. T. cruzi has an NAD-linked
α-hydroxy acid dehydrogenase (HADH) that is similar to
the lactate dehydrogenase X isozyme of mammalian sperm-
atozoa, which has two isozymes. Isozyme I of this enzyme
is responsible for the weak lactate dehydrogenase activity
found in T. cruzi, whereas isozyme II is active towards α-
ketocaproate and α-ketoisocaproate. Furthermore, because
isozyme II is involved in the oxidation of NADH to NAD+
during glycolysis, it plays an important role in the pathways
that supply energy to T. cruzi [21]. α-Ketocaproate and
α-ketoisocaproate, which are derived from leucine and iso-
leucine by transamination, also participate in the NADH
shuttle system that transfers reducing equivalents from the
cytosol to the mitochondria [22]. Inhibitors that block the
activity of HADH-isozyme II could therefore be used to in-
hibit both glycolysis and the NADH shuttle system [23-26],
which would lead a significant decrease in the energy being
supplied to T. cruzi and the death of the parasite.
We have shown that N-allyl oxamate (NAOx), N-propyl
oxamate (NPOx) and N-isopropyl oxamate (NIPOx) are
selective inhibitors of HADH-isozyme II, based on the
chemical structures of the compounds being similar to
those of the isozyme II substrates, α-ketocaproate and
α-ketoisocaproate. Although these oxamates were un-
able to penetrate intact T. cruzi, the corresponding hydro-
phobic ethyl esters (i.e., Et-NAOx, Et-NPOx and Et-NIPOx)
successfully penetrated intact parasites and exerted trypa-
nocidal activity [27,28]. Et-NAOx, Et-NPOx and Et-NIPOx
also exhibited inhibitory activity towards amastigote nests
[29]. It was envisaged that the non-specific aliphatic and
aromatic carboxyl esterases found in T. cruzi [30,31] would
hydrolyze these esters after they had penetrated the T. cruzi
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activity of HADH-isozyme II and kill the T. cruzi. In this
context, the esters of NPOx would be behaving as pro-
drugs, in the sense that they must undergo a metabolic
conversion process before becoming an active pharma-
cological drug [32].
In this study, we have investigated the development of
an efficient prodrug for the treatment of Chagas disease
by esterifying NPOx with a compound more hydropho-
bic than ethyl alcohol. Benzyl alcohol was selected be-
cause as an appropriate alcohol for the esterification of
NPOx not only because of its high hydrophobicity, but
also because it is a well-known antimicrobial agent [33].
The high lipophilicity of the benzyl ester of NPOx (B-
NPOx) would allow it enter intact parasites more effect-
ively, and its subsequent enzymatic cleavage would re-
sult in the release the inhibitor NPOx and benzyl
alcohol, which would exert a dual trypanocidal effect on
T. cruzi parasites. B-NPOx was synthesized and charac-
terized as part of the current study, and its activity was
evaluated on T. cruzi epimastigotes and trypomastigotes
(in vitro), as well as the blood and tissues of T. cruzi in-
fected mice (in vivo), using five T. cruzi strains. The ac-
tivity of B-NPOx was also compared with those of the
reference drugs Bz and Nx.
Methods
Chemicals
NAD, NADH, pyruvate, α-ketoisocaproate sodium salt and
N-ethylmaleimide were obtained from Sigma Chemical
Co. (St. Louis, MO, USA). Nifurtimox was purchased from
Bayer (Munich, Germany) and benznidazole was from
Roche (Basel, Switzerland). NPOx and Et-NPOx were syn-
thesized according to previously reported methods [24].
All of the chemicals used in the current study were of the
highest purity available.
Synthesis of the benzyl ester of N-propyl oxamate (B-
NPOx)
A solution of propylamine (0.1 mol) in ether (50 mL)
was added in a dropwise manner to an ice-cold solution
of dibenzyl oxalate (0.1 mol) in a 4:1 (v/v) mixture of
diethyl ether and chloroform (250 mL), and the result-
ing mixture was stirred for 2 h at 5°C. The reaction
mixture was then warmed to room temperature and
stirred overnight. The benzyl alcohol produced during
the reaction was subsequently removed by distillation
at 50–60°C/1 mmHg to give a cloudy residue, which
was dissolved in diethyl ether (10 mL) and held for 12 h
at 5°C. A crystalline product formed with a melting
point of 64–65°C, which was collected by filtration.
The filtrate was evaporated to dryness under reduced
pressure and then fractionated under vacuum. B-NPOx
distilled at 60–65°C/1 mmHg as a colorless oil, whichcrystallized on standing. The crystals were purified by
recrystallization from chloroform to give the desired
product in an overall yield of 86% with a melting point of
50–55°C. The final product was analyzed by IR, 1H-NMR,
13C-NMR and HRMS. IR KBr (Perkin Elmer GX spectrom-
eter; Perkin Elmer, Waltham, MA, USA): 3292 (N-H),
3036, 2966 (C-H, aromatic), 1785 (C = O), 1514 (C = C),
1377 (C-H methyl), 1222 (C-N-C), 898 (C-O-C), 765, 895
(aromatic, monosubstituted) cm-1. 1H-NMR (Jeol JNM-
GSX270 spectrometer; Jeol, Pleasanton, CA, USA):
(270 MHz, CDCl3) δ 0.91 (t, J = 7.4 Hz, 3H, CH3), 1.53
(s, 2H, CH2), 3.25 (q, J = 7.2 Hz, 2H, CH2), 5.29 (s, 2H,
CH2), 7.1 (bs, 1H, NH), 7.32–7.37 (m, 5H, H phenyl).
13C-NMR (Jeol JNM-GSX270): (67.5 MHz, CDCl3) δ
11.37 (CH3), 22.46 (CH2Me), 41.69 (CH2-NH), 68.64
(CH2-O), 128.72 (Co,m phenyl), 128.87 (Cp phenyl), 134.47
(Cipso phenyl), 156.38 (CO-NH), 160.75 (COO). HRMS
(Bruker micrOTOF-Q II 10392 spectrometer; Bruker,
BioSpin Co. Billerica, MA, USA): Calcd for C12H15NO3:
m/z = 221.2524 [M]+; found m/z = 221.1085 [M]+. These
results confirmed that our synthesis of B-NPOx was
successful.Determination of the cytotoxicity of NPOx, Et-NPOx and
B-NPOx
The cytotoxic activities of NPOx, Et-NPOx and B-NPOx
were evaluated against monkey kidney epithelial cells
(Vero cell line) using an alamar blue (Invitrogen, Life
Technologies, Sacramento, CA. USA) viability assay. The
cells were cultured in standard culture medium (MEM
with 10% fetal bovine serum) in 24-well plates (7.5 × 103
cells/well) to 80% confluence. Increasing concentrations
of NPOx, Et-NPOx and B-NPOx (0.1–3 mM) in 5 μL of
ethyl alcohol were added to each well. The medium was
replaced after 24, 48 and 72 h of incubation (37°C, 5%
CO2 and 95% relative humidity) with 200 μL of fresh
medium containing alamar blue, and the fluorescence of
each well was measured using a Perkin Elmer LS 55 spec-
trofluorometer (Perking Elmer, Waltham, MA, USA). Cell
viability (%) was measured relative to the control wells
(cultured in medium alone) according to the following
calculation: Cell viability (%) = (fluorescencetest × 100%)/
fluorescencecontrol.Determination of the toxicity of Et-NPOx and B-NPOx on
mice
The median lethal dose (LD50) values of Et-NPOx and
B-NPOx were determined in NIH male albino mice
(18–20 g), according to the established requirements
[34]. Et-NPOx and B-NPOx were orally administered
as solutions in a 5% Arabic gum in water at doses of
1.5–3.0 g/kg of body weight. The drugs were adminis-
tered on a daily basis for 50 days.
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The T. cruzi strains used in the current study were iso-
lated from triatomines and chagasic patients. The Parra
and Compostela strains of T. cruzi were isolated from
Triatoma longipennis. The Nayarit strain of T. cruzi was
isolated from Triatoma picturata, and the NINOA
(MHOM/MX/1994/Ninoa) and INC-5 (MHOM/MX/
1994/INC-5) strains were isolated from chronic chagasic
patients living in two endemic areas of Mexico [35]. The
NINOA and INC-5 strains correspond to the prevalent
discrete typing unit (DTU) classification designated as
TcI, and it is also likely that the Parra, Compostela and
Nayarit strains belong to the same TcI classification [36]
as the other strains of Mexican T. cruzi characterized to
date [35]. Following their isolation, the strains were
maintained in triatomine bugs (Meccus longipennis) and
by serial passages in NIH male albino mice [37].
Culture of Trypanosoma cruzi epimastigotes
Cardiac blood samples from NIH male albino mice that
had been individually infected with the different T. cruzi
strains were cultured at 28°C in liver infusion tryptose
(LIT) broth supplemented with 10% heat-inactivated
fetal calf serum [38]. When the growth of the epimasti-
gotes became exponential, they were collected from the
liquid phase by centrifugation at 3000 × g for 15 min.
The resulting pellet was then washed three times with
20 volumes (with respect to the pellet) of buffer contain-
ing 0.1 M sodium phosphate (NaH2PO4/Na2HPO4) and
0.15 M NaCl (pH 7.4) and resuspended in the same buf-
fer at 1 × 106 epimastigotes/mL. This suspension was
then aliquoted (1 mL) in Eppendorf tubes. All of these
procedures were carried out at 4°C.
Trypanosoma cruzi homogenates and enzyme
preparations
One milliliter samples of the T. cruzi suspensions de-
scribed above were subjected to three cycles of freezing
in liquid nitrogen and thawing at room temperature.
The disruption of the parasites was monitored by the
microscopic examination of the resulting homogenate,
which was frozen at –20°C until it was required for the
experiments. There was no discernible decrease in the
HADH-isozyme II activity of the homogenates after
2 months in storage at –20°C. The homogenates were
thawed at room temperature immediately prior to be
used in the enzymatic assays, and centrifuged at 1200 ×
g for 20 min at 4°C. The supernatant of each homogen-
ate (enzyme preparation) was used to analyze the
HADH-isozyme II activity. HADH-isozyme II was puri-
fied as previously described [21]. The homogenates were
prepared without any protease inhibitor, which could
inhibit the aliphatic and aromatic carboxyl esterase ac-
tivities described in T. cruzi [30,31].Quantification of α-hydroxy acid dehydrogenase isozyme
II activity
HADH-isozyme II activity was measured spectrophotomet-
rically by following the oxidation of NADH (λ = 340 nm,
ε = 6220 M-1 cm-1) with α-ketoisocaproate as a substrate
[21]. Each assay mixture contained, in a final volume of
3 mL, 0.12 mM NADH, 0.1 M sodium phosphate
(NaH2PO4/Na2HPO4) plus 0.15 M NaCl (pH 7.4) buffer,
5 mM neutral sodium salt of α-ketoisocaproate, and the
purified enzyme or an enzyme preparation from the
homogenate of each one of the five T. cruzi strains. The
purified enzyme or enzyme preparation was diluted
with the 0.1 M sodium phosphate plus 0.15 M NaCl
(pH 7.4) buffer prior to being used to allow for a shift
in the absorbance at 340 nm of 0.05–0.08 nm/min with
5 mM α-ketoisocaproate. The assay mixtures were incu-
bated at 37°C either alone or in the presence of NPOx, Et-
NPOx or B-NPOx, and changes in the absorption at
340 nm were recorded over a 5 min period. In some cases,
1 mM of N-ethylmaleimide, which is a known inhibitor of
T. cruzi carboxylesterases [31], was added to the assay mix-
tures. The activity of HADH-isozyme II was subsequently
expressed as the percentage of ΔE 340 nm/min, where the
velocity in the absence of an inhibitor was considered to be
100%. The results were then plotted against the concentra-
tions of NPOx, Et-NPOx or B-NPOx (0.05–1 mM).
Trypanocidal activity of B-NPOx towards cultured
epimastigotes
Epimastigotes (1 × 106 units/mL) of the five T. cruzi strains
in the 0.1 M sodium phosphate plus 0.15 M NaCl (pH 7.4)
buffer were used to evaluate the trypanocidal activity of
B-NPOx. Nine hundred and eighty microliters of the epi-
mastigote suspension was placed in an Eppendorf tube,
followed by 20 μL of ethyl alcohol or benzyl alcohol or an
ethyl alcohol solution of NPOx, Et-NPOx, B-NPOx, Nx or
Bz, at a final concentration in the range of 0.1–3 mM.
After being incubated at 28°C for 10, 20, 30, 40, 50 and
60 min, the number of live parasites was determined in a
Neubauer haemocytometer [39] using the trypan blue dye
exclusion method. The mean number of live epimastigotes
in the control group, which was not subjected to any drug
treatment, was taken as 100%. The results were subse-
quently given as the mean values ± the standard deviations
of three independent experiments for the viability of the
epimastigotes [24].
To measure the penetration of B-NPOx into the epimas-
tigotes, a suspension of epimastigotes (1 × 106 units/mL)
in 980 μL of the 0.1 M sodium phosphate plus 0.15 M
NaCl (pH 7.4) buffer was mixed with 20 μL of the 1 mM
solution of B-NPOx in ethyl alcohol. After being incubated
at 28°C for 15, 30 and 45 min, the samples were centri-
fuged at 3000 × g and the supernatants were analyzed
spectrophotometrically at 248 nm, which corresponds to
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ance of the supernatants at 248 nm correlated well with the
penetration of B-NPOx into the epimastigotes.Trypanocidal activity of B-NPOx on bloodstream
trypomastigotes
Bloodstream trypomastigotes of each one of the five
T. cruzi strains were obtained by cardiac puncture from
NIH male albino mice at the peak of parasitaemia. One
hundred and ninety-five microlitre aliquots of blood con-
taining 1 × 106 trypomastigotes were added to each well of
a sterile 96-well plate, followed by 5 μL of NPOx, Et-NPOx,
B-NPOx, Nx or Bz at final concentrations in the range of
0.1–3 mM. Stock solutions of NPOx, Et-NPOx, B-NPOx
and the reference drugs in DMSO were prepared and sub-
sequently diluted with sterile distilled water to give a final
DMSO concentration of 1%. Blood containing 1 × 106 try-
pomastigotes with 1% DMSO was used as a control. The
plates were incubated at 4°C for 24 h and the trypanocidal
effects of the compounds were determined by comparing
the motilities of the trypomastigotes at the different con-
centrations with the control. The results were subsequently
presented as the mean values ± the standard deviations of
the number of mobile (viable) trypomastigotes from three
independent experiments.Effect of B-NPOx on the parasitaemia and amastigote
nests in infected mice
NIH male albino mice (18–20 g) were inoculated intraper-
itoneally with 1 × 103 bloodstream trypomastigotes of each
of the five different T. cruzi strains. The mice were divided
in five groups (10 mice per group), including (1) those
without any treatment (control group, infected/untreated),
and those treated with (2) Bz, (3) Nx, (4) Et-NPOx or (5)
B-NPOx. The four test compounds were orally adminis-
tered as solutions in 5% Arabic gum in water at a dose of
100 mg/Kg [7] per day over a period of 50 days. The first
dose was given 24 h after the infection. Levels of parasit-
emia, beginning 24 h after infection, were determined
every other day in a Neubauer hemocytometer using 5 μL
of blood, which was collected from the tail vein of the in-
fected mice and diluted at a ratio of 1:10 (v/v) with a satu-
rated solution of ammonium chloride [39]. The reduction
in the parasitemia was evaluated by comparing the num-
ber of trypomastigotes obtained at each time point after
the administration of NPOx, Et-NPOx, B-NPOx, Bz or Nx
with the number of trypomastigotes obtained at the same
point in infected/untreated mice, which was taken as 100%
[29]. The experimental protocols for animal care and use
were reviewed and approved by the Bioethics Committee
of our Institution according to the “Guide for the care and
use of laboratory animals”, which was published by the US
National Institute of Health [40].To evaluate the activity of B-NPOx towards amastigote
nests, we obtained tissue samples from the hearts and left
legs (skeletal muscle) of mice from each of the five groups
described above either 30 or 50 days after infection. The
tissue samples were fixed with formaldehyde, dehydrated
and embedded in paraffin. Sections of the samples (3 μm
thick) were then stained with hematoxylin and eosin and
analyzed by light microscopy. Fifty randomly selected
microscopic fields from at least three mice were examined
to quantify the number of amastigote nests. The mean
number of amastigote nests in the infected/untreated
group was taken as 100% [29].
Results
B-NPOx inhibits the activity of α-hydroxy acid
dehydrogenase-isozyme II in homogenates from T. cruzi
strains
B-NPOx did not inhibit the activity of purified HADH-
isozyme II (Figure 1A), and the same effect was reported
previously for Et-NPOx [24]. However, B-NPOx did effect-
ively inhibit the activity of the homogenates derived from
the NINOA strain of T. cruzi, and its inhibitory activity
was higher than those of NPOx and Et-NPOx (Figure 1B).
When the T. cruzi homogenates were incubated with N-
ethylmaleimide, which is an inhibitor of T. cruzi carbox-
ylesterases [31], prior to being treated with B-NPOx or
Et-NPOx, the inhibitory activity of these compounds
decreased (Figure 1B). However, the activity of purified
HADH-isozyme II was unaffected by the presence of N-
ethylmaleimide (Figure 1A). Notably, NADH was not
oxidized when α-ketoisocaproate was not added to the
homogenates (Figure 1B). Similar results were obtained
with the other four T. cruzi strains (data not shown).
B-NPOx exhibited higher trypanocidal activity towards
epimastigotes and blood trypomastigotes than Et-NPOX,
Bz and Nx
B-NPOx penetrated into the epimastigotes of the NINOA
strain of T. cruzi. When a suspension of the epimastigotes
were incubated with 1 mM B-NPOx for 15, 30 and
45 min, the concentration of B-NPOx in the supernatants
decreased by 9–15%, 30–34% and 40–46%, respectively.
B-NPOx exhibited a higher trypanocidal activity towards
the epimastigotes of the NINOA strain of T. cruzi than Et-
NPOx, Bz and Nx at concentrations in the range of 0.1–
1 mM (Figure 2A). The trypanocidal activity of B-NPOx
was 4.4-fold higher than that of Bz at a concentration of
1 mM. Benzyl alcohol also exhibited trypanocidal activity
by itself, which was higher than those of Et-NPOx, Bz and
Nx (Figure 2A). The combination of benzyl alcohol and
NPOx had a similar trypanocidal activity to that of benzyl
alcohol alone. In contrast, ethyl alcohol had no trypanoci-
dal activity (data not shown). B-NPOx also exhibited a
higher trypanocidal activity towards the epimastigotes of
Figure 1 B-NPOx did not inhibit the activity of purified HADH-isozyme II but did exhibit an inhibitory effect towards T. cruzi homogenates.
(A) Effects of B-NPOx, Et-NPOx, NPOx and N-ethylmaleimide (0.05–1 mM) on the activity of purified HADH-isozyme II in the presence of 5 mM
α-ketoisocaproate and 0.12 mM NADH. Changes in the absorption at 340 nm were recorded over a 5 min period. The enzymatic activity was
expressed as a percentage of ΔE 340 nm/min, where Vmax was 100%. (B) Effects of B-NPOx, B-NPOx + N-ethylmaleimide, Et-NPOx, Et-NPOx +
N-ethylmaleimide and NPOx (0.05–1 mM) on the enzymatic activities of the T. cruzi homogenates. The N-ethylmaleimide concentration was
1 mM and the reaction conditions were set as in (A). As controls, the effects of B-NPOx, Et-NPOx and NPOx on the T. cruzi homogenates were
assayed in the absence of α-ketoisocaproate. The kinetic assays have been reported as the mean values ± the standard deviation from three
independent experiments.
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fold) and Miguz (8.1-fold) strains of T. cruzi than Bz. Fur-
thermore, the Miguz and Compostela strains of T. cruzi
were resistant to Bz and Nx (compared with the untreated
epimastigotes) (Figure 2B). The activity of B-NPOx was also
higher than that of Et-NPOx towards the epimastigotes of
the INC-5 (2-fold), Compostela (2.6-fold), Nayarit (3.75-
fold), NINOA (4.3-fold Figure 2A) and Miguz (5.5-fold)strains of T. cruzi (Figure 2B). Notably, benzyl alcohol ex-
hibited trypanocidal activity towards four of the T. cruzi
strains tested in this study (data not shown).
B-NPOx exhibited the highest trypanocidal activity of all
of the compounds tested towards blood trypomastigotes of
the NINOA strain of T. cruzi at concentrations in the
range of 0.1–1 mM. The activity of B-NPOx at 1 mM was
6.6-fold greater than that of Bz towards the NINOA strain
Figure 2 B-NPOx exhibited higher in vitro trypanocidal activity than Et-NPOX or the reference drugs Bz and Nx. (A) The viability of intact NINOA
T. cruzi epimastigotes was evaluated using 1 × 106 epimastigotes/mL after they had been treated with 0.1–3 mM B-NPOx, Et-NPOx, NPOx, Nx, Bz
or benzyl alcohol (B-OH) every 10 min for 60 min at 28°C. The data shown correspond to an incubation period of 60 min. Viability was calculated
as the number of live parasites, which was quantified using the trypan blue dye exclusion method. The control, which was set to 100%, represents
the viability of the untreated epimastigotes. The results have been reported as the mean values ± the standard deviations for the viabilities of the
epimastigotes from three independent experiments. (B) The effects of 1 mM B-NPOx, Et-NPOx, Bz and Nx towards the epimastigotes of the Miguz,
Compostela, Nayarit and INC-5 strains of T. cruzi were evaluated under the conditions described in (A). (C) The viability of intact NINOA T. cruzi
bloodstream trypomastigotes was evaluated based on the motility of 1 × 106 bloodstream trypomastigotes/mL following their treatment with
B-NPOx, Et-NPOx, NPOx, Bz or Nx (0.1–3 mM) in 1% DMSO for 24 h at 4°C. Blood containing 1 × 106 trypomastigotes and 1% DMSO was used as
a control. The results have been presented as the mean values ± the standard deviations for the viability of bloodstream trypomastigotes from
three independent experiments. (D) The effects of 1 mM B-NPOx, Et-NPOx, Nx and Bz on 1 × 106 bloodstream trypomastigotes/mL from the
Miguz, Compostela, Nayarit and INC-5 strains of T. cruzi were evaluated under the conditions described in (C). Data were analyzed in (B) and
(D) with one-way ANOVA followed by Tukey’s multiple comparisons test. ***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05, compared with the control.
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Nayarit (2-fold), INC-5 (3.7-fold), Compostela (4.2-fold)
and Miguz (24-fold) strains of T. cruzi (Figure 2D). The ac-
tivity of B-NPOx was also higher than that of Et-NPOx to-
wards the Compostela (2.9-fold), INC-5 (3.9-fold), Nayarit
(4.5-fold), NINOA (4.9-fold Figure 2C) and Miguz (14.8-
fold) strains of T. cruzi. Blood trypomastigotes were found
to be slightly more sensitive to the compounds than the
epimastigotes, and the trypomastigotes of the Miguz strain
were sensitive to Bz and Nx at p < 0.05 (Figure 2D). Benzyl
alcohol also exhibited trypanocidal activity towards the
blood trypomastigotes of all five of the different strains of
T. cruzi tested in the current study, and the results for the
NINOA strain are shown in Figure 2C.B-NPOx reduced parasitemia in infected mice more
effectively than Et-NPOX, Bz or Nx
The parasitemia in mice infected with the NINOA strain of
T. cruzi was detectable 10 days after infection, and reached
its maximum value 25 days after infection before becoming
non-detectable after 50 days of infection (Figure 3A). After
50 days of infection, the trypomastigotes infect new cells
and become intracellular amastigotes [41]. The parasitemia
induced by the Miguz and Compostela strains of T. cruzi
was detectable 25–30 days after infection and reached its
peak at 40–45 days, before becoming non-detectable after
55 days of infection. In contrast, the parasitemia induced by
the Nayarit and INC-5 strains of T. cruzi was detectable
5 days after infection and reached its peak at 15–20 days
Figure 3 B-NPOx led to a greater reduction in the parasitemia in infected mice than Et-NPOX, Bz or Nx. (A) Parasitemia was evaluated according to the
number of bloodstream trypomastigotes in mice infected with the NINOA strain of T. cruzi and subsequently treated with B-NPOx, Et-NPOx, Bz or Nx as
indicated in the Methods section. A group of infected/untreated mice was used as a control group. The drugs were administered daily at 100 mg/kg over
a period of 50 days. The first dose was given 24 h after the infection. The results have been presented as the mean values ± the standard deviations of
the parasitemia from three different experiments. (B) The effects of B-NPOx, Et-NPOx, Bz and Nx towards the parasitemia in mice infected with the Miguz,
Compostela, Nayarit and INC-5 strains of T. cruzi were evaluated under the conditions indicated in (A). The percentage of blood trypomastigotes was
calculated on the day of maximum parasitemia for all four of the different T. cruzi strains (i.e., 40–45 days after infection with the Miguz and Compostela
strains, 15–20 days after infection with the Nayarit and INC-5 strains), and the parasitemia in the control (infected/untreated) group was set to 100% in
each case. Data were analyzed with one-way ANOVA followed by Tukey’s multiple comparisons test. ***p≤ 0.001, **p≤ 0.01, *p≤ 0.05, compared with
the infected/untreated mice.
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tion, as previously described [28].
B-NPOx led to a significant reduction in parasitemia
in mice infected with the NINOA strain of T. cruzi
compared with the infected/untreated mice (Figure 3A).
B-NPOx caused the greatest reduction in parasitemia
of all of the compounds tested in the current study,
with the biggest reduction occurring between 10 and
20 days after infection (Figure 3A). For example, B-NPOx
was found to be 15-fold more efficient than Bz at day 20.B-NPOx was also found to be more effective than Bz
towards the Nayarit (1.9-fold), Compostela (2.5-fold),
INC-5 (3.5-fold) and Miguz (5.4-fold) strains of T. cruzi
(Figure 3B). It is noteworthy that the Miguz and Com-
postela strains of T. cruzi were resistant to treatment
with Nx and Bz (Figure 3B). B-NPOx was also found to
be more effective than Et-NPOx for treating the
NINOA (2.2-fold, Figure 3A), Compostela (2.3-fold),
Nayarit (2.9-fold), INC-5 (3.2-fold) and Miguz (4.5-
fold) strains of T. cruzi (Figure 3B).
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sitemia was assessed, and no significant differences were
found in the erythrocyte count in any of the mice groups
infected with any of the five T. cruzi strains and treated
with B-NPOx and Et-NPOx tested in the current study.
The erythrocyte counts were always in the range of
6,000,000–10,000,000/mL in all of the mice, which is con-
sidered normal [42], and there was therefore no evidence
to suggest that B-NPOx and Et-NPOx were exhibiting
hemolytic effects. B-NPOx and Et-NPOx were not found
to be cytotoxic towards Vero cells (85% or more cells were
viable) at concentrations of up to 2 mM. The daily admin-
istration of Et-NPOx and B-NPOx for 50 days did not
cause any overt tissue alterations in the mice. The LD50
values of B-NPOx and Et-NPOx were 2.00 and 2.32 g/kg
of body weight, respectively, which indicated that these
compounds are not toxic in mice [34].
B-NPOx was more effective to reduce amastigote nests in
infected mice than Et-NPOX, Bz and Nx
The number of amastigote nests found in the heart and
skeletal muscles of the mice treated with B-NPOx was
significantly reduced compared with the infected/un-
treated mice, as shown for the Nayarit (2.6-fold) and
Miguz (4.6-fold) strains of T. cruzi in Figure 4A. This ef-
fect was also higher than that found in mice treated with
Et-NPOx or Bz. It is noteworthy that the Miguz strain of
T. cruzi was resistant to Bz (Figure 4A). There were no
significant differences in the number of amastigote nests
found in the heart and skeletal muscles of any one
group. Similar results were also found with the NINOA
(2.1-fold), INC-5 (3.4-fold) and Compostela (4.1-fold)
strains (data not shown). The effects of Nx were lower
than those of Bz (data not shown). Histological analysis
of the myocardium and the skeletal muscles of mice in-
fected with the NINOA and INC-5 strains that had been
treated with B-NPOx showed a significantly reduction in
the size of the amastigote nests, as shown for the
NINOA strain in Figure 4B and without any inflamma-
tory infiltrate (Figure 4B).
Discussion
The aim of the current study was to develop an efficient
prodrug for the treatment of Chagas disease using a
murine model of the disease. With this in mind, we de-
signed and synthesized B-NPOx, and subsequently eval-
uated its activity towards five different strains of T. cruzi
relative to those of Et-NPOx and the reference drugs Bz
and Nx. In our previous study, we demonstrated that
NPOx is an effective and selective inhibitor of HADH-
isozyme II of T. cruzi [24]. Unfortunately, however, NPOx
is a very polar molecule and can therefore not penetrate in-
tact epimastigotes, because cellular membranes are hydro-
phobic barriers that block the diffusion of polar substances.In contrast, the hydrophobic compound Et-NPOx has been
reported to enter intact epimastigotes and exhibit trypano-
cidal activity [24,27].
The results of the current study have shown that
B-NPOx behaves in the same way as Et-NPOx towards
purified HADH-isozyme II, in the sense that it did not in-
hibit its activity, but B-NPOx did exhibit significant inhibi-
tory activity towards T. cruzi homogenates, because the
homogenates contain aromatic and aliphatic non-specific
carboxyl esterases [30,31] that can release the NPOx in-
hibitor. In the presence of N-ethylmaleimide, which is an
inhibitor of the carboxylesterases [30,31], the inhibitory
activities of B-NPOx and Et-NPOx towards the T. cruzi
homogenates were reduced to less than 10% of their ori-
ginal values. Notably, N-ethylmaleimide did not inhibit
the activity of purified HADH-isozyme II. These findings
strongly support the mechanism that we proposed for the
activity of the esters of NPOx. Briefly, following the pene-
tration of the hydrophobic prodrug B-NPOx or Et-NPOx
into T. cruzi and its subsequent hydrolysis to release the
NPOx inhibitor (Figure 5), the inhibition of HADH-
isozyme II by NPOx would block the oxidation of NADH,
which would lead to a significant decrease in the energy
supply that would ultimately kill the T. cruzi parasites.
The lipophilicity of B-NPOx was measured in terms of
its partition coefficient LogP (i.e., octanol:water log par-
tition coefficient), which was determined using the CAS
System of the American Chemical Society [43,44]. The
LogP values for NPOx and Et-NPOx were determined to
be 0.487 and 1.52, respectively. Given that B-NPOX is a
novel compound, its LogP value has not been published
in the literature, although this number can be calculated
by the sum of the hydrophobic contributions of the “par-
ent” molecule and its corresponding substituents [43].
For B-NPOX, the “parent” molecule would be the methyl
ester of N-propyl oxamate (Me-NPOx) (LogP = 1.013)
minus one proton (0.225). The substituent in this case
would be benzene minus one proton (LogP = 1.90), and so
the sum of these values would give a calculated LogP
value of 2.688 for B-NPOX. Based on these results, the li-
pophilicity of B-NPOX would be 1.77-fold higher than
that of Et-NPOX.
The high lipophilicity of B-NPOx would allow it pene-
trate more readily through the T. cruzi membranes, which
would lead to higher concentrations of B-NPOx inside the
T. cruzi parasites compared with Et-NPOx. The presence
of higher concentrations of B-NPOx inside the parasite
would consequently lead to higher levels of NPOx follow-
ing the hydrolysis of the prodrug, which would inhibit the
activity of HADH-isozyme II. The high trypanocidal activ-
ity of B-NPOx can also be attributed to the effect of the
benzyl alcohol, which is released from B-NPOx during its
hydrolysis inside the parasites. As a result of the high lipo-
philicity of B-NPOx and the dual inhibitory effects of
Figure 4 B-NPOx was more effective than Et-NPOX, Bz and Nx in terms of its ability to reduce amastigote nests in infected mice. (A) The effects
of B-NPOx, Et-NPOx and Bz (daily dosing at 100 mg/kg for 30 or 50 days) on the amastigote nests were evaluated using tissue slices (3 μm thick)
of the heart and skeletal muscles of mice infected with the Nayarit and Miguz strains of T. cruzi (these mice were the same than those studied in
Figure 3). The tissue slices were stained with hematoxylin/eosin and analyzed by light microscopy. Fifty randomly selected microscopic fields from
at least three mice were examined to quantify the number of amastigote nests. The mean number of amastigote nests in the infected/untreated
group was set as 100%. Data were analyzed with one-way ANOVA followed by Tukey’s multiple comparisons test. ***p≤ 0.001, **p≤ 0.01, *p≤ 0.05,
compared with the infected/untreated mice. (B) Histological studies of the myocardium and skeletal muscle of mice infected with the NINOA strain of
T. cruzi. Samples of the myocardium (a, b) and skeletal muscle (c, d) from infected/untreated mice (a, c) or of mice (b, d) treated with B-NPOx at
100 mg/kg over 50 days. Tissue slices stained with hematoxylin/eosin were analyzed at 40× magnification. The arrows indicate the amastigote nests.
The images are representative of three different experiments.
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higher level of trypanocidal activity than Et-NPOx or Bz.
The activities of B-NPOx towards the epimastigotes, try-
pomastigotes and parasitaemia of the five different strains
of T. cruzi tested in the current study were 2- to 5.5-fold,
2.9- to 14.8-fold and 2.2- to 4.5-fold higher than those of
Et-NPOx, respectively. Furthermore, the activities of
B-NPOx towards the epimastigotes, trypomastigotes and
parasitaemia of the five different strains of T. cruzi testedin the current study were 2.1 to 8.1-fold, 2- to 24-fold and
1.9- to 15-fold greater than those of Bz, respectively. The
effects of Nx were always lower than those of Bz. It is
noteworthy that B-NPOx exhibited trypanocidal activity
and reduced the parasitemia produced by Miguz and
Compostela strains of T. cruzi, which were resistant to
treatment with Bz and Nx. Taken together, these results
suggest that B-NPOx could be used as a bi-potential pro-
drug for the treatment of Chagas disease.
Figure 5 Proposed mechanism for the trypanocidal activity of the benzyl and ethyl esters of NPOx. B-NPOx and Et-NPOx would diffuse through
the cellular membrane of T. cruzi, where they would be hydrolyzed by intracellular aliphatic and aromatic carboxyl esterases to give NPOx, which
is a selective and competitive inhibitor of HADH-isozyme II. Et-NPOx would also give the inactive ethyl alcohol, whereas B-NPOx would give
benzyl alcohol, which is a well know antimicrobial agent that also exhibits trypanocidal activity (as we demonstrated here). B-NPOx would
therefore exhibit dual trypanocidal activity resulting from NPOx and benzyl alcohol. Furthermore, the lipophilicity of B-NPOx was found to be
1.76-fold greater than that of Et-NPOx, which would allow it to penetrate more effectively into T. cruzi than Et-NPOx to give a higher level of
trypanocidal activity.
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inhibition and bacterial killing) can be explained by its
inhibition of several membrane proteins and its ability
to cause changes in cell membrane fluidity [45,46]. The
trypanocidal activity of benzyl alcohol, which has been
reported for the first time in this study, could also be ex-
plained by similar mechanisms.
These findings demonstrate that B-NPOx was the
most effective of all of the compounds tested in the
current study against the infective (blood trypomasti-
gotes) and the reproductive (amastigotes) forms of T.
cruzi in mice. Blood trypomastigotes have a vigorous
motility, which allows for their rapid extravasation and
dissemination within the host, where they invade fibro-
blasts, macrophages and epithelial cells. Once in these
cells, trypomastigotes can undergo differentiation into
amastigotes. Mobile trypomastigotes subsequently emerge
from amastigote nests, leading to the rupture of the in-
fected cells during the chronic stage of the disease [5].
The dual effect of B-NPOx against the infective and the
reproductive forms of T. cruzi provides strong evidence
in support of the use of B-NPOx as a potent therapeutic
prodrug for the treatment of Chagas disease.
In addition to its ability to inhibit the activity of
HADH-isozyme II, treatment with NPOx also leads to
an increase in the concentrations of the HADH-isozymeII substrates α-ketocaproate and α-ketoisocaproate, which
are derived from leucine and isoleucine through trans-
amination reactions. It is therefore possible that NPOx
also affects the metabolism of these amino acids and
that these changes could play a critical role in the killing
of T. cruzi. It is expected that the long evolutionary dis-
tance between trypanosomatids and their mammalian
hosts would allow for the selective inhibition of the en-
zymes belonging to the trypanosomatids without affect-
ing the host enzymes [20].
B-NPOx was not found to be cytotoxic and there was
no evidence of hemolytic damage or overt tissue alter-
ation in mice treated with B-NPOx for 50 days. The
doses of B-NPOx administered to the mice (100 mg/kg of
body weight) were 20-fold lower than that its LD50 value.
B-NPOx is made up of two polar compounds that can be
eliminated from the host (humans or animals) through
phase II metabolism processes (e.g., esterification). In con-
trast, other drugs commonly used for the treatment of
Chagas disease, such as Nx, Bz and fexinidazole (which is
commonly used in human African trypanosomiasis and in
experimental models of Chagas disease [1]), are highly
toxic non-polar molecules that are difficult to eliminate
[14]. These properties lend further support to the idea that
B-NPOx could potentially be used as a therapeutic pro-
drug for the treatment of Chagas disease.
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one drug preparation (multi-potential drug) has been de-
scribed previous as a general strategy to increase the thera-
peutic efficacy of the individual components [32,47,48].
B-NPOx is a bi-potential prodrug, and the strategy re-
ported in the current study could be used to introduce
other antimicrobial agents, besides benzyl alcohol, into T.
cruzi. We are currently studying the effects of B-NPOx on
the promastigotes and amastigotes of Leishmania (an-
other member of the Trypanosomatidae family), which
probably contain an aromatic α-hydroxy acid dehydro-
genase, as well as several other α-hydroxy acid dehydro-
genases [49].
Additional pharmacological and toxicological studies
of the effects of B-NPOx on other animals are required
to fully evaluate its usefulness as a therapeutic prodrug
for the treatment of Chagas disease. The results pre-
sented in the current study could have a significant im-
pact on human health because there are currently no
drugs available for the effective treatment of Chagas dis-
ease. This disease affects millions of people in Latin
America, and so the search for new drugs against T.
cruzi is of utmost importance and must be continued.
Conclusions
B-NPOx exhibited a higher trypanocidal effects than
Et-NPOx both in vitro (2- to 14.8-fold) towards epimas-
tigotes and trypomastigotes and in vivo (2.2- to 4.5-fold)
towards the blood trypomastigotes and tissues of mice in-
fected with the five different strains of T. cruzi. B-NPOx
also exhibited greater activities in vitro (2- to 24-fold) and
in vivo (1.9- to 15-fold) compared with the Bz and Nx.
The higher lipophilicity of B-NPOx compared with Et-
NPOx (1.77-fold) could be responsible for its better
penetration into T. cruzi, where its enzymatic cleavage
would result in the release of the NPOx inhibitor and
benzyl alcohol, which both exhibit sufficiently high levels
of trypanocidal activity to kill T. cruzi. Taken together
with its low toxicity, these results therefore indicate that
B-NPOx could be used as a potent therapeutic prodrug
for the treatment of Chagas disease.
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